Vemircopan (ALXN2050): A Comprehensive Pharmacological and Clinical Analysis of a Discontinued Factor D Inhibitor

1.0 Executive Summary

Vemircopan (ALXN2050) was an orally bioavailable, second-generation small-molecule inhibitor of complement Factor D, a critical serine protease in the alternative pathway of the complement system. The drug was originated by Achillion Pharmaceuticals and subsequently developed by Alexion, and later AstraZeneca, following its landmark acquisition of Alexion. Positioned as a potential best-in-class agent, Vemircopan was designed to address significant unmet needs in several complement-mediated diseases, most notably Paroxysmal Nocturnal Hemoglobinuria (PNH). The strategic rationale for its development was compelling: to offer an oral therapy that could not only match the efficacy of market-leading intravenous C5 inhibitors but also potentially control both intravascular and extravascular hemolysis, a key limitation of the existing standard of care.

Preclinical data for Vemircopan were highly promising, suggesting enhanced potency, lower clearance, and superior bioavailability compared to its predecessor, danicopan. This profile supported the hypothesis that Vemircopan could achieve the sustained and complete alternative pathway inhibition necessary for effective monotherapy in PNH. Initial interim data from a Phase 2 proof-of-concept study in treatment-naïve PNH patients appeared to validate this hypothesis, showing clinically meaningful improvements in hemoglobin levels, near-normalization of lactate dehydrogenase (LDH), and a favorable short-term safety profile. These results generated considerable optimism and supported the progression of the clinical program.

However, as clinical development advanced and longer-term, more comprehensive data became available, a starkly different picture emerged. The promising early results in PNH proved unsustainable. The program was ultimately terminated due to the drug's failure to adequately control intravascular hemolysis, leading to significantly increased rates of breakthrough hemolysis and LDH excursions compared to the standard of care. Concurrently, parallel Phase 2 programs evaluating Vemircopan in generalized Myasthenia Gravis (gMG), IgA Nephropathy (IgAN), and Lupus Nephritis (LN) were also discontinued. The portfolio-wide termination was officially attributed to an unfavorable risk-benefit profile based on accumulating safety and efficacy data from these mid-stage trials.

The discontinuation of the Vemircopan program in early 2025 resulted in a substantial financial impact for AstraZeneca, which recorded a $753 million impairment charge. This figure underscores the high initial valuation of the asset and the significant future potential that was lost. The failure of Vemircopan, a key pipeline asset from the Alexion acquisition, serves as a critical case study in the challenges of developing oral small-molecule inhibitors for powerful biological amplification cascades, the translational gap between preclinical promise and clinical reality, and the inherent risks in high-value biopharmaceutical M&A.

2.0 Molecular Profile and Physicochemical Characteristics

A comprehensive understanding of a drug candidate begins with its fundamental chemical and physical identity. These properties govern its formulation, stability, interaction with biological systems, and ultimately, its potential as a therapeutic agent. This section details the nomenclature, chemical structure, and key physicochemical properties of Vemircopan.

2.1 Nomenclature and Identifiers

Vemircopan has been identified by a variety of names and codes throughout its development and in scientific and regulatory databases. Consistency in identification is critical for accurate data aggregation and analysis. The International Nonproprietary Name (INN) assigned to the molecule is Vemircopan.[1] During its development by Achillion Pharmaceuticals and later Alexion AstraZeneca Rare Disease, it was referred to by the development codes ALXN2050, ACH-5228, and ACH-0145228.[1]

For cross-referencing across major chemical and drug databases, Vemircopan is assigned the following unique identifiers:

• DrugBank ID: DB18012 [1]
• CAS Number: 2086178-00-7 [1]
• PubChem CID: 126642840 [1]
• FDA UNII: HN6I4K50QB [1]
• ChEMBL ID: CHEMBL4650325 [1]
• NCI Thesaurus Code: C174393 [1]
• KEGG ID: D12481 [1]

2.2 Chemical Structure and Formula

Vemircopan is classified as a small molecule belonging to several chemical classes, including amides, azabicyclo compounds, halogenated hydrocarbons, indazoles, and pyrimidines.[6] Its molecular complexity is a key feature influencing its synthesis and pharmacological properties.

• Chemical Formula: The empirical formula for Vemircopan is .[1]
• IUPAC Name: The systematic name according to the International Union of Pure and Applied Chemistry (IUPAC) nomenclature is (1R,3S,5R)-2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl]-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide.[1]
• Structural Representations: For computational chemistry and database searching, the structure is represented by the following standardized strings:
• SMILES: CC1=C(N=C(C=C1)Br)NC(=O)[C@@H]2C[C@]3(C[C@H]3N2C(=O)CN4C5=C(C=C(C=C5)C6=CN=C(N=C6)C)C(=N4)C(=O)C)C.[1]
• InChIKey: OCXAGXCMZACNEC-CTWZREHQSA-N.[1]

The chemical structure of Vemircopan is notably complex, featuring a rigid 2-azabicyclo[3.1.0]hexane core, multiple chiral centers that define its specific stereochemistry ((1R,3S,5R)), and several heterocyclic ring systems (indazole, pyrimidine, pyridine). This structural intricacy suggests a sophisticated and likely multi-step synthetic process would be required for its manufacture. Such complexity often correlates with higher manufacturing costs and challenges in process optimization and scale-up. For an oral drug intended for chronic administration in rare but lifelong diseases, the cost of goods sold (COGS) is a critical determinant of commercial viability. Therefore, the inherent difficulty in synthesizing Vemircopan would have been a background consideration throughout its development, potentially impacting its long-term financial projections even if it had demonstrated clinical success.

2.3 Physicochemical Properties

The physical and chemical properties of Vemircopan dictate its behavior in both laboratory and physiological environments.

• Molecular Weight: The calculated molecular weight is approximately 602.5 g/mol (values range from 602.48 to 602.5 g/mol across sources).[1]
• Appearance: In its solid state, Vemircopan is described as a solid powder.[3]
• Solubility: The molecule demonstrates solubility in dimethyl sulfoxide (DMSO), a common solvent for in vitro biological assays. A specific solubility of 50 mg/mL (equivalent to 82.99 mM) in DMSO has been reported, with the note that ultrasonic assistance may be required to achieve dissolution, further indicating its challenging physical properties.[3]
• Storage Conditions: For laboratory use, recommended storage is at 2-8°C for short-term stability (days to weeks) and at -20°C for long-term storage (months to years) to maintain chemical integrity.[3]

The following table provides a consolidated reference for the key identifiers and properties of Vemircopan.

Table 2.1: Key Identifiers and Chemical Properties of Vemircopan

Property	Value	Source(s)
International Nonproprietary Name (INN)	Vemircopan	1
DrugBank ID	DB18012	1
CAS Number	2086178-00-7	1
FDA UNII	HN6I4K50QB	1
Molecular Formula		1
Molecular Weight	602.48 g/mol	3
IUPAC Name	(1R,3S,5R)-2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl]-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	1
InChIKey	OCXAGXCMZACNEC-CTWZREHQSA-N	1
SMILES	CC1=C(N=C(C=C1)Br)NC(=O)[C@@H]2C[C@]3(C[C@H]3N2C(=O)CN4C5=C(C=C(C=C5)C6=CN=C(N=C6)C)C(=N4)C(=O)C)C	1
Solubility (DMSO)	50 mg/mL (82.99 mM); requires ultrasonic assistance	4
Appearance	Solid Powder	3

3.0 Pharmacology: Targeting the Alternative Complement Pathway

The therapeutic strategy of Vemircopan was rooted in the precise modulation of the complement system, a fundamental component of the innate immune system. Its mechanism of action was designed to intervene at a critical upstream checkpoint, offering a distinct pharmacological approach compared to established complement-targeting therapies.

3.1 The Role of Factor D and the Alternative Pathway (AP) in Disease

The complement system is a cascade of plasma proteins that acts as a primary defense against pathogens and a mediator of inflammation. It can be activated through three main routes: the classical, lectin, and alternative pathways (AP). The AP is unique in that it is subject to constant, low-level spontaneous activation (a process known as "tickover") and serves as a powerful amplification loop for all three activation pathways.[8] Dysregulation or overactivation of the AP is a key driver of tissue damage in a range of autoimmune and inflammatory disorders.[8]

Central to the activation of the AP is Factor D (FD), also known as adipsin or complement factor D (CFD). Factor D is a serine protease that circulates in the blood in its active form but has an extremely low concentration and a highly specific substrate.[1] Its sole known function is to cleave Factor B after Factor B has bound to C3b on a cell surface, forming the C3bB complex. This cleavage event generates the fragments Ba and Bb. The larger fragment, Bb, remains associated with C3b to form the

AP C3 convertase ().[11] This enzyme is the engine of the AP amplification loop; it cleaves vast quantities of C3 into C3a (an anaphylatoxin) and C3b. The newly generated C3b can then deposit on surfaces and bind more Factor B, creating more C3 convertase and leading to an explosive amplification of the complement response.[8] Because Factor D is essential for the formation of the AP C3 convertase and is present at the lowest concentration of any complement component, it is considered the rate-limiting enzyme of the alternative pathway.[11]

In diseases like Paroxysmal Nocturnal Hemoglobinuria (PNH), red blood cells lack the protective proteins CD55 and CD59, making them highly susceptible to complement-mediated destruction.[14] The uncontrolled amplification of the AP on these cells leads to two primary mechanisms of hemolysis:

1. Intravascular Hemolysis (IVH): The downstream cascade leads to the formation of the membrane attack complex (MAC, C5b-9), which directly lyses red blood cells in circulation.[14]
2. Extravascular Hemolysis (EVH): Massive opsonization of red blood cells with C3b fragments flags them for destruction by macrophages in the liver and spleen.[15]

3.2 Vemircopan's Inhibitory Mechanism and Pharmacodynamics

Vemircopan was developed as an orally bioavailable, small-molecule inhibitor designed to specifically and potently block the function of Factor D.[1] Upon administration, Vemircopan targets, binds to, and inhibits the catalytic activity of the Factor D serine protease.[11]

By blocking Factor D, Vemircopan directly prevents the cleavage of Factor B into Ba and Bb. This action effectively halts the formation of the AP C3 convertase (), thereby shutting down the entire AP amplification loop at its rate-limiting step.[1] The intended pharmacodynamic effect was the immediate, complete, and sustained inhibition of the alternative pathway. This would, in turn, prevent the generation of downstream effectors, blocking both C3b deposition (and thus EVH) and MAC formation (and thus IVH), offering a comprehensive treatment for the hemolysis seen in PNH and preventing tissue damage in other complement-mediated diseases.[1]

A key element of Vemircopan's development story is its relationship to danicopan, a first-in-class oral Factor D inhibitor also from the Achillion/Alexion pipeline. While danicopan showed promise, its use as a monotherapy was associated with suboptimal control of IVH in some patients.[16] Vemircopan was engineered as a next-generation molecule to overcome this limitation. Preclinical studies demonstrated that Vemircopan possessed enhanced

in vitro potency and a superior pharmacokinetic profile in animal models, with lower clearance and higher bioavailability compared to danicopan.[13] This improved profile was rationally designed with the goal of achieving more consistent and complete Factor D target engagement in humans, thereby providing the robust control of IVH that danicopan monotherapy lacked. The ultimate failure of Vemircopan to achieve this specific goal suggests that the challenge may be more fundamental to the target or drug class than to the specific properties of a single molecule.

3.3 Comparative Pharmacology: Positioning Against Other Complement Inhibitors

The therapeutic landscape for complement-mediated diseases, particularly PNH, is defined by different strategies for inhibiting the cascade. Vemircopan's mechanism as a proximal inhibitor of the alternative pathway positioned it uniquely against the established standard of care.

Table 3.1: Comparison of Mechanisms for Key Complement Inhibitors in PNH

Drug Class	Example Drug(s)	Target	Mechanism of Action	Effect on Hemolysis (IVH/EVH)	Route of Administration
Terminal C5 Inhibitors	Eculizumab, Ravulizumab	Complement C5	Monoclonal antibodies that bind C5, preventing its cleavage into C5a and C5b. Blocks MAC formation.	Effectively controls IVH. Does not prevent C3b deposition, leading to residual EVH.	Intravenous Infusion
Proximal C3 Inhibitors	Pegcetacoplan	Complement C3/C3b	A PEGylated peptide that binds C3 and C3b, blocking cleavage and all downstream effects.	Controls both IVH and EVH by acting upstream of C5 and preventing opsonization.	Subcutaneous Infusion
Proximal Factor B Inhibitors	Iptacopan	Factor B	Oral small molecule that inhibits Factor B, preventing formation of the AP C3 convertase.	Controls both IVH and EVH by blocking the AP amplification loop.	Oral
Proximal Factor D Inhibitors	Danicopan, Vemircopan	Factor D	Oral small molecules that inhibit Factor D, preventing formation of the AP C3 convertase.	Theoretically controls both IVH and EVH by blocking the AP at its rate-limiting step.	Oral

The primary distinction is between proximal and terminal inhibition. Terminal C5 inhibitors like eculizumab (Soliris®) and ravulizumab (Ultomiris®) have been transformative in PNH by effectively blocking MAC formation and controlling life-threatening IVH.[9] However, by leaving the upstream part of the cascade intact, they allow for the continued deposition of C3b fragments on PNH red blood cells, leading to clinically significant EVH in a subset of patients who may remain anemic and transfusion-dependent.[14]

Vemircopan, as a proximal inhibitor, was designed to address this limitation. By acting upstream at Factor D, it aimed to halt the entire AP cascade, thereby preventing both C3b-mediated EVH and MAC-mediated IVH.[11] This dual mechanism was the central value proposition for Vemircopan and other proximal inhibitors like the Factor B inhibitor iptacopan (Fabhalta®).[8]

This strategy, however, carries a significant pharmacological challenge. Targeting the rate-limiting enzyme of a powerful biological amplification loop with an oral small molecule requires maintaining drug concentrations above a therapeutic threshold continuously. Unlike long-acting monoclonal antibodies such as ravulizumab, which provide stable, saturating target engagement for weeks [9], small molecules are subject to pharmacokinetic fluctuations between doses. If the trough concentration of Vemircopan were to dip below the level required for complete Factor D inhibition, the AP amplification loop could rapidly reactivate, leading to an acute episode of breakthrough hemolysis. The clinical trial data ultimately demonstrated that this was a fatal flaw in the monotherapy approach for Vemircopan, as it led to unacceptable rates of BTH and LDH excursions.[19] This suggests that the high bar for sustained, flawless inhibition required to control the AP may be exceedingly difficult to achieve with the pharmacokinetic profile of an oral small molecule.

4.0 Nonclinical and Phase 1 Clinical Program

Before a drug candidate can be evaluated in patients with a specific disease, it must undergo a rigorous program of nonclinical testing and Phase 1 clinical trials. These foundational studies are designed to establish a scientific rationale for its use, characterize its behavior in humans, and define a safe and appropriate dose range for further investigation. Vemircopan was supported by an extensive and well-planned early-stage development program.

4.1 Preclinical Rationale

The decision to advance Vemircopan into clinical trials was based on a solid foundation of preclinical research. In vitro and animal studies were conducted to characterize its potency, selectivity, and metabolic stability, and to demonstrate its efficacy in disease-relevant models.[13] A key component of this preclinical package was the direct comparison with its predecessor, danicopan. These studies established that Vemircopan was a more potent inhibitor of Factor D and possessed superior pharmacokinetic properties in animal models, including lower clearance and higher oral bioavailability.[13] This enhanced profile provided a clear rationale for its clinical investigation, as it was specifically designed to overcome the perceived limitations of danicopan, particularly the goal of achieving more consistent and complete alternative pathway inhibition to enable effective monotherapy for PNH.[13]

4.2 Phase 1 Studies in Healthy Volunteers

Following the promising preclinical results, Alexion initiated a comprehensive Phase 1 program to assess the safety, tolerability, and pharmacokinetics (PK) of Vemircopan in healthy human volunteers. The breadth of these studies indicates a significant investment and a thorough, conventional approach to early clinical development. Multiple Phase 1 trials were completed, confirming that the fundamental absorption, distribution, metabolism, and excretion (ADME) properties of the drug were characterized.[13]

Key components of the Phase 1 program included:

• Formulation Optimization: A study was conducted to investigate the pharmacokinetic profile of modified-release prototype formulations compared to an immediate-release reference tablet in 80 healthy participants (NCT05780645).[13] This effort to optimize the drug's release profile suggests a focus on improving its PK characteristics, likely to ensure sustained target coverage and potentially improve tolerability or convenience.
• Drug-Drug Interaction (DDI) Assessment: A dedicated DDI study in 60 healthy participants (NCT06071442) evaluated the potential for interactions between Vemircopan and several commonly co-administered drugs: rosuvastatin (a statin), metformin (an anti-diabetic agent), levonorgestrel/ethinyl estradiol-containing oral contraceptives, and carbamazepine (an anti-epileptic).[13] Such a study is a standard regulatory requirement and demonstrates a commitment to understanding the drug's safety profile in a real-world context where polypharmacy is common.
• Evaluation in Special Populations: To understand how Vemircopan should be used in patients with organ dysfunction, studies were initiated in participants with renal impairment (NCT04623710) and hepatic impairment (NCT05259085).[19] These trials are crucial for defining dosing guidelines for these vulnerable populations.

The extensive and methodically planned Phase 1 program underscores the high level of commitment and significant resources that Alexion and AstraZeneca dedicated to Vemircopan's development. It was clearly viewed as a high-priority asset with blockbuster potential. However, an early sign of trouble can be seen in the status of the hepatic impairment study (NCT05259085). This trial was terminated prematurely in August 2024 by a "Sponsor decision".[19] The termination of a supportive Phase 1 study typically occurs when a program is being de-prioritized or when emerging data from pivotal efficacy trials cast doubt on the drug's future. Given that the announcements of the Phase 2 trial terminations in PNH, gMG, and IgAN/LN followed in the subsequent months (December 2024 to March 2024) [6], the halt of the hepatic impairment study can be interpreted as a leading indicator of the program-wide issues that were becoming apparent internally. It represented the first step in mitigating further investment in an asset with a declining probability of success.

5.0 Clinical Development in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH) was the lead indication for Vemircopan and the therapeutic area where its potential was most eagerly anticipated. The development program in PNH was designed to establish proof-of-concept for Vemircopan as a monotherapy capable of controlling both intravascular and extravascular hemolysis. The trajectory of this program, from highly promising interim data to an eventual declaration of failure, provides a critical narrative of the drug's clinical journey.

5.1 Trial Design and Endpoints (NCT04170023)

The cornerstone of the PNH program was a Phase 2, open-label, multi-group, proof-of-concept study registered as NCT04170023.[16] The study was designed to evaluate the efficacy, safety, and PK/PD of Vemircopan monotherapy in different PNH patient populations, including those who were treatment-naïve, those switching from the C5 inhibitor eculizumab, and those rolling over from danicopan monotherapy.[16]

The most significant publicly available data came from the cohort of 11 treatment-naïve adult patients with PNH characterized by active hemolysis and anemia.[16] Key design elements for this cohort included:

• Inclusion Criteria: Patients were required to have a lactate dehydrogenase (LDH) level of 1.5 times the upper limit of normal (ULN), an absolute reticulocyte count (ARC) of 100 x /L, and a hemoglobin (Hgb) level of <10.5 g/dL.[16]
• Dosing Regimen: Treatment was initiated with Vemircopan 120 mg administered orally twice daily (BID). The protocol included a provision for dose escalation to 180 mg BID if a patient demonstrated an inadequate response. Triggers for escalation included a failure to increase Hgb by 1 g/dL by week 4, the need for a blood transfusion, or an LDH level >1.5 × ULN on two consecutive assessments after day 14.[16]
• Study Periods: The trial consisted of a 12-week primary treatment period, followed by a long-term extension of up to 96 weeks.[16]
• Endpoints: The primary efficacy endpoint was the change from baseline in Hgb level at week 12. Key secondary endpoints were designed to provide a comprehensive assessment of hemolysis control and clinical benefit, including the change from baseline in LDH level, transfusion avoidance, change in ARC, and change in patient-reported fatigue as measured by the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) scale.[16]

5.2 Analysis of Interim Efficacy and Safety Data (ASH 2022 Presentation)

Interim results from the treatment-naïve cohort of the NCT04170023 study were presented at the 65th American Society of Hematology (ASH) Annual Meeting in December 2022. The data, based on the first 12 weeks of treatment for 9 evaluable patients, were highly encouraging and suggested that Vemircopan was achieving its therapeutic goals.[16]

Efficacy Findings:

• Hemoglobin Improvement: The primary endpoint was met, with a mean increase in Hgb from baseline of 3.9 g/dL at week 12. This represented a substantial improvement in anemia.[16]
• Control of Intravascular Hemolysis: LDH levels, a key biomarker of IVH, were reduced by a mean of 81% by week 12, reaching a level of 1.4 × ULN, which is near the target for optimal disease control (<1.5 × ULN).[16]
• Reduction in Transfusion Burden: Transfusion avoidance was achieved in 8 of 9 patients (89%) through the 12-week period.[16]
• Improvement in Fatigue: Patients reported a clinically meaningful improvement in fatigue, with a mean increase of 13.3 points on the FACIT-Fatigue scale, where an increase of >5 points is considered significant.[16]

Safety Findings:

At the time of the interim analysis, Vemircopan was reported to be well-tolerated. No serious adverse events (SAEs), Grade ≥3 AEs, discontinuations due to AEs, or deaths were reported. The most frequently reported treatment-emergent adverse event (TEAE) was headache, occurring in 4 of 11 patients (36.4%). No thrombotic events or meningococcal infections (a known risk for complement inhibitors) were observed.16

Based on this positive dataset, the investigators concluded that Vemircopan monotherapy provided proof-of-concept in PNH by controlling IVH, preventing clinically significant EVH (as inferred from the Hgb increase and reticulocyte count reduction), and improving patient symptoms. The data were deemed sufficient to warrant the planning of Phase 3 trials.[16]

Table 5.1: Summary of Efficacy and Safety Results from NCT04170023 (Interim Analysis of Treatment-Naïve Cohort)

Endpoint	Metric	Result at Week 12	Source(s)
Efficacy
Change in Hemoglobin (Hgb)	Mean Increase from Baseline (g/dL)	+3.9	16
Transfusion Avoidance	Percentage of Patients (%)	89	16
Lactate Dehydrogenase (LDH)	Mean Percent Reduction from Baseline (%)	81 (reduced to 1.4 x ULN)	16
Change in FACIT-Fatigue Score	Mean Increase from Baseline (points)	+13.3	16
Safety
Any Adverse Event (AE)	Percentage of Patients (%)	81.8	18
Any Serious Adverse Event (SAE)	Percentage of Patients (%)	0	18
Related AEs	Percentage of Patients (%)	36.4	18
Most Common AEs (>1 patient)	Headache, Vomiting	36.4%, 18.2%	18

5.3 Rationale for Termination: The Unraveling of the PNH Program

Despite the highly optimistic public presentation of interim data, the PNH program for Vemircopan was ultimately terminated in March 2024.[19] The reason provided for this decision stands in stark contrast to the earlier results. The trial was halted because Vemircopan, as a monotherapy, "did not appropriately control IVH" and was associated with "significantly increased rates of BTH [breakthrough hemolysis] and LDH excursions (LDH excursions is defined by LDH values > 2xULN) compared to ravulizumab".[19]

This final outcome reveals a critical disconnect between the average treatment effect and the consistency of that effect over time. While the mean improvements in Hgb and LDH reported in the interim analysis were impressive, the ultimate reason for failure points to an unacceptable level of variability and intermittent loss of disease control. For a life-threatening condition like PNH, where the standard of care provides stable and continuous complement blockade, the occurrence of breakthrough hemolysis is a critical failure. The comparison to ravulizumab, a long-acting C5 inhibitor known for its stable control, highlights that Vemircopan could not meet this essential clinical benchmark.

An early warning sign of this underlying issue was evident even in the positive interim data: 7 of the 11 enrolled patients (64%) required dose escalation from 120 mg BID to 180 mg BID.[16] This high rate of up-titration suggests that the initial dose was suboptimal for a majority of patients and that the drug may have a narrow therapeutic window, making it difficult to maintain adequate drug exposure consistently.

The failure of Vemircopan monotherapy, even after being rationally designed to be more potent than danicopan, has significant implications. It suggests that achieving the flawless, sustained Factor D inhibition required to suppress the AP amplification loop with an oral small molecule is exceptionally challenging. This experience led AstraZeneca to abandon the monotherapy approach for Vemircopan entirely. Unlike danicopan, which was successfully pivoted to an add-on therapy to C5 inhibitors to treat EVH [13], no such rescue strategy was pursued for Vemircopan. This strategic choice implies either that the commercial opportunity for a second add-on agent was deemed insufficient, or that emerging data on Vemircopan's long-term safety or PK profile made it unsuitable even for this alternative role.

6.0 Evaluation in Other Complement-Mediated Diseases

In parallel with the lead PNH program, Alexion and AstraZeneca initiated Phase 2 clinical trials to evaluate Vemircopan in other diseases where complement system dysregulation is a known pathogenic factor. The simultaneous development across multiple therapeutic areas reflected the company's belief in the broad potential of Factor D inhibition. However, the eventual termination of these programs alongside the PNH trial indicated a fundamental, platform-wide issue with the drug candidate.

6.1 Generalized Myasthenia Gravis (gMG) Program (NCT05218096)

Generalized myasthenia gravis is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness. In a significant subset of patients, the disease is driven by autoantibodies against the acetylcholine receptor (AChR), which activate the complement cascade at the neuromuscular junction, leading to tissue damage and impaired neuromuscular transmission.[19] This clear link to complement-mediated pathology made gMG a logical indication for Vemircopan.[20]

A Phase 2, randomized, double-blind, placebo-controlled, multicenter study (NCT05218096) was initiated to evaluate the efficacy and safety of Vemircopan in adult participants with gMG.[27]

• Trial Design: The study was designed to assess two oral doses of Vemircopan, 120 mg and 180 mg, against a placebo. The trial structure included an 8-week Primary Evaluation Period (PEP) followed by a 26-week Extended Treatment Period (ETP) and a subsequent open-label extension.[27]
• Endpoints: The primary outcome measure was the change from baseline in the Quantitative Myasthenia Gravis (QMG) total score at Week 8, a standardized physician-assessed scale of disease severity. Secondary endpoints included changes in the patient-reported MG-Activities of Daily Living (MG-ADL) score.[27]
• Status and Outcome: The trial successfully enrolled 70 participants. However, it was terminated prematurely in April 2024.[19] The reason for the termination was cited as a "Sponsor decision".[19] While specific efficacy or safety data leading to this decision are not detailed in the available materials, the timing, in conjunction with the failure in other indications, points toward an unfavorable risk-benefit assessment.

6.2 IgA Nephropathy (IgAN) and Lupus Nephritis (LN) Program (NCT05097989)

Both IgA Nephropathy and Lupus Nephritis are serious autoimmune kidney diseases characterized by immune complex deposition and subsequent complement activation, leading to inflammation, glomerular damage, proteinuria, and progressive loss of kidney function.[6] The involvement of the alternative complement pathway in the pathogenesis of both diseases provided a strong rationale for investigating a Factor D inhibitor.[20]

A single, combined Phase 2 study (NCT05097989) was designed to evaluate Vemircopan in these two related nephrological indications.[28]

• Trial Design: This was a randomized, double-blind, placebo-controlled, multicenter study evaluating Vemircopan at doses of 120 mg and 180 mg as an add-on to standard-of-care background therapy in adult patients with either proliferative LN or IgAN.[28] The study plan included a 26-week initial evaluation period and a 24-week extended treatment period.[28]
• Endpoints: The primary endpoint for both the IgAN and LN cohorts was the percentage change in proteinuria from baseline to Week 50, as measured by a 24-hour urine collection. Proteinuria is a key biomarker of kidney damage and a primary endpoint in modern nephrology trials.[28]
• Status and Outcome: The trial was terminated in December 2024, well before its planned completion.[6] The broader program discontinuation was attributed to a "lack of efficacy" and unfavorable "safety and efficacy data".[32]

The concurrent failure of Vemircopan across three distinct and mechanistically plausible therapeutic areas—hematology (PNH), neurology (gMG), and nephrology (IgAN/LN)—is highly significant. It strongly suggests that the drug's downfall was not due to an incorrect hypothesis in a single disease model but rather to a fundamental flaw in the drug's properties when tested in humans. This could manifest as a platform-wide inability to achieve the necessary level of target engagement and pharmacodynamic effect to produce a clinical benefit, or the emergence of an unacceptable safety profile that became apparent as the number of patients and the duration of exposure increased across the various studies. The consistent failure across the portfolio sealed the fate of the entire Vemircopan program.

7.0 Integrated Safety and Tolerability Assessment

A comprehensive evaluation of a drug's safety profile is paramount and often dictates its ultimate success or failure. The safety narrative for Vemircopan evolved significantly over the course of its clinical development, from initial reports of good tolerability to becoming a key factor in the decision to terminate the entire program.

7.1 Early Phase and PNH Trial Safety

The earliest available safety data from patients treated with Vemircopan came from the interim analysis of the NCT04170023 study in PNH. As reported at the ASH 2022 meeting, the safety profile over the initial 12-week treatment period in 11 treatment-naïve patients appeared favorable.[16] Key findings from this initial assessment included:

• No serious adverse events (SAEs) were reported.
• No Grade 3 adverse events (AEs) occurred.
• No AEs led to discontinuation of the study drug or death.
• The most common treatment-emergent adverse event was headache, which was reported in 4 of 11 patients (36.4%).[16]

Based on this limited, short-term dataset, Vemircopan was described as "well tolerated," and no new safety signals were identified.[16] This initial safety profile, combined with the promising efficacy data, supported the optimistic outlook for the program at the time.

7.2 Broader Safety Concerns and Program Termination

This initially benign safety narrative was ultimately superseded by broader concerns that emerged as the clinical program matured. AstraZeneca's official press release and communications regarding the discontinuation of the Vemircopan program explicitly stated that the decision was "based on safety and efficacy data" from the mid-stage studies.[33]

While specific details of the adverse events observed in the terminated gMG (NCT05218096) and IgAN/LN (NCT05097989) trials are not provided in the available documentation, the company's statement is a definitive acknowledgment that the risk-benefit profile had become unfavorable. The evolution from a "well-tolerated" profile in a small, 12-week PNH study to a program-wide termination citing safety concerns is a classic example of a common drug development pitfall. Safety signals that are absent, rare, or appear mild in small, short-duration Phase 1 and early Phase 2 studies can become more frequent, more severe, or newly apparent as a larger and more diverse patient population is exposed to the drug for longer periods. The gMG and nephrology trials involved more patients (70 in the gMG study) and planned for longer treatment durations (up to 50 weeks or more) than the initial PNH cohort, providing a much more robust dataset for safety evaluation.[27] It is within these larger, longer-term datasets that the safety issues contributing to the program's halt likely emerged.

7.3 Data Gaps and Interpretation

It is crucial to acknowledge that without access to the final clinical study reports or detailed data from the terminated trials, a definitive conclusion on the specific nature of the safety events cannot be drawn. The public record lacks information on the type, severity, and frequency of the adverse events that drove the decision. However, the logical interpretation of the available information is that the cumulative safety data from across the entire clinical program revealed a safety and tolerability profile that, when combined with the observed lack of compelling efficacy (particularly the failure to control BTH in PNH), was no longer supportive of continued development. The initial clean safety profile appears to have been a function of limited exposure, which was not representative of the drug's true risk profile over time.

8.0 Strategic Analysis of Program Discontinuation

The decision to terminate a late-stage clinical program is a significant event for any pharmaceutical company, involving a complex interplay of clinical data, commercial projections, and portfolio strategy. The discontinuation of Vemircopan by AstraZeneca provides a compelling case study in R&D decision-making and the financial realities of biopharmaceutical development.

8.1 Corporate Communications and Rationale

AstraZeneca formally announced the termination of all Vemircopan development in its pipeline update for the fourth quarter of 2023, released in early February 2025.[6] The company's public statements provided a multi-faceted rationale that varied slightly by indication but pointed to an overall program failure.

• Overarching Rationale: The global termination of the program was attributed to a comprehensive review of Phase 2 "safety and efficacy data".[33] This broad statement indicates that the drug's risk-benefit profile was deemed unacceptable across the board.
• PNH-Specific Rationale: For the lead indication of PNH, the reason for failure was more specific and technical. The Phase 2 trial (NCT04170023) was halted because Vemircopan failed to adequately control intravascular hemolysis and led to "significantly increased rates of BTH [breakthrough hemolysis] and LDH excursions" when compared to the existing standard of care, ravulizumab.[19] This points to a clear failure to meet the primary efficacy bar required for a PNH monotherapy.
• Nephrology-Specific Rationale: For the Phase 2 trial in IgA Nephropathy and Lupus Nephritis (NCT05097989), the termination was attributed to a "lack of efficacy".[32]
• gMG-Specific Rationale: The Phase 2 trial in generalized Myasthenia Gravis (NCT05218096) was halted due to a "Sponsor decision," a common term used when a program is discontinued for strategic reasons, often informed by an unfavorable assessment of emerging data.[19]

8.2 Financial Impact

The strategic decision to abandon Vemircopan had a direct and substantial financial consequence for AstraZeneca. The company recorded a $753 million impairment charge related to the termination of the asset.[13] This accounting measure represents the write-down of the intangible asset value assigned to Vemircopan on AstraZeneca's balance sheet, which was established at the time of the Alexion acquisition.

The magnitude of this write-down is highly informative. It is not merely a reflection of sunk R&D costs but a quantitative measure of the lost future economic potential that the company had once attributed to the drug. A charge of this size signifies that Vemircopan was not considered a minor, exploratory project but a high-value asset with projected blockbuster revenue streams across its multiple indications. The decision to accept such a significant financial loss, rather than attempting to salvage the program through alternative strategies (e.g., exploring different doses, narrower patient populations, or an add-on indication), strongly implies that the clinical data were so conclusively negative that no commercially viable path forward could be justified.

8.3 Context within the Alexion Acquisition

Vemircopan was a central piece of the pipeline that AstraZeneca acquired in its $39 billion takeover of Alexion in 2021.[13] At the time of the deal, and in subsequent investor communications, Vemircopan was highlighted as a key new molecule with the potential to drive "incremental rare disease growth" beyond Alexion's established C5 inhibitor franchise of Soliris and Ultomiris.[32] Its failure, therefore, represents a significant setback for the R&D component of the acquisition strategy.

This setback was not an isolated incident. The discontinuation of Vemircopan followed the termination of other ex-Alexion pipeline assets, including ALXN1840 for Wilson disease and ALXN1820 for sickle cell disease.[32] This pattern of post-acquisition pipeline failures underscores the inherent risk in large-scale M&A, where the valuation of clinical-stage assets is a critical and challenging component of due diligence.

Despite these pipeline disappointments, AstraZeneca's leadership has consistently defended the Alexion acquisition as a strategic success. In response to the Vemircopan write-down, CEO Pascal Soriot described the acquisition as "fantastic," framing the pipeline attrition as a normal and expected part of the biopharmaceutical industry.[32] This perspective is supported by the exceptional commercial performance of the on-market assets, Soliris and Ultomiris, which have delivered substantial revenue growth for AstraZeneca's rare disease division.[33] This situation highlights a common dynamic in "pipeline-in-a-product" acquisitions: while the deal may be justified by the combined value of commercial products and a promising pipeline, the near-term value is often overwhelmingly driven by the established products. The failure of Vemircopan and other Alexion assets serves as a cautionary example that the R&D component of such deals carries a very high degree of risk, and its contribution to future growth is far from guaranteed, even for assets that appear promising at the time of acquisition.

9.0 Conclusion: Lessons from the Vemircopan Program

The development and subsequent discontinuation of Vemircopan (ALXN2050) provides a series of valuable lessons for the fields of complement biology, clinical development, and pharmaceutical strategy. The program's trajectory from a scientifically rational, chemically optimized candidate to a portfolio-wide clinical failure encapsulates many of the core challenges inherent in modern drug development.

9.1 Summary of Findings

Vemircopan was a potent, second-generation oral inhibitor of Factor D, rationally designed to offer a comprehensive, convenient treatment for PNH and other complement-mediated diseases. Its preclinical profile was superior to its predecessor, and promising interim Phase 2 data in PNH suggested it was on a path to success. However, this early promise did not translate into a viable therapeutic. The final analysis revealed two fatal flaws:

1. Inadequate Efficacy in PNH: As a monotherapy, Vemircopan failed to provide the consistent, reliable control of intravascular hemolysis that is the benchmark for PNH treatment, leading to unacceptable rates of breakthrough hemolysis.
2. Unfavorable Platform-Wide Risk-Benefit: The simultaneous termination of programs in gMG, IgAN, and LN, officially attributed to a combination of safety and efficacy concerns, indicates a fundamental issue with the drug's performance in humans that transcended any single disease pathology.

The program's failure culminated in a $753 million financial write-down, marking the end of a significant investment and a key strategic asset within AstraZeneca's rare disease pipeline.

9.2 Implications for Complement Inhibitor Development

The Vemircopan story offers several critical insights for the future of complement-targeted therapies:

• The High Bar for Oral Monotherapy in PNH: The failure of Vemircopan underscores the immense difficulty of displacing highly effective, long-acting biologic therapies with oral small molecules in diseases requiring continuous, profound pathway inhibition. The inherent pharmacokinetic variability of oral agents poses a significant risk of transient sub-therapeutic exposure, which can lead to clinically catastrophic events like breakthrough hemolysis. This sets an exceptionally high bar for the required PK/PD profile of any new oral monotherapy in this space.
• The Perils of the Translational Gap: Vemircopan serves as a stark reminder of the translational gap between preclinical models and human clinical outcomes. Despite demonstrating enhanced in vitro potency and superior pharmacokinetics in animal models compared to danicopan, these advantages did not manifest as superior clinical efficacy. This highlights the limitations of preclinical data in predicting the complex interplay of drug exposure, target engagement, and clinical response in human disease.
• The Future of Factor D Inhibition: The contrasting fates of Vemircopan (terminated) and danicopan (approved as an add-on therapy) suggest a potential strategic path for the Factor D inhibitor class. While achieving the flawless AP inhibition required for effective monotherapy in PNH may be exceedingly difficult, the mechanism remains highly valuable for controlling the C3-mediated extravascular hemolysis that persists in C5 inhibitor-treated patients. The future of this class may lie primarily in combination therapy, where it can complement the action of terminal complement inhibitors, rather than attempting to replace them. The complete discontinuation of Vemircopan raises the important question of whether its failure was specific to the molecule or indicative of a broader, class-wide limitation for monotherapy.

Ultimately, the Vemircopan program, while unsuccessful, has contributed valuable knowledge to the field. It has refined the understanding of the pharmacological requirements for targeting the alternative complement pathway and provided a sobering, data-driven case study on the risks and complexities of translating promising science into a successful medicine.

10.0 Appendices

Appendix A: Comprehensive List of Chemical Identifiers and Synonyms

Identifier Type	Value
International Nonproprietary Name (INN)	Vemircopan
Development Codes	ALXN2050; ACH-5228; ACH-0145228; ALXN-2050
DrugBank ID	DB18012
CAS Number	2086178-00-7
PubChem CID	126642840
FDA UNII	HN6I4K50QB
ChEMBL ID	CHEMBL4650325
NCI Thesaurus Code	C174393
KEGG ID	D12481
Systematic Name (1)	(1R,3S,5R)-2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl]-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
Systematic Name (2)	2-Azabicyclo(3.1.0)hexane-3-carboxamide, 2-(2-(3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methyl-2-pyridinyl)-5-methyl-, (1R,3S,5R)-

Appendix B: Summary Table of Key Clinical Trials

NCT Number	Phase	Indication(s)	Enrollment	Status
NCT04170023	2	Paroxysmal Nocturnal Hemoglobinuria (PNH)	29	Terminated
NCT05218096	2	Generalized Myasthenia Gravis (gMG)	70	Terminated
NCT05097989	2	IgA Nephropathy (IgAN) & Lupus Nephritis (LN)	N/A	Terminated
NCT05259085	1	Hepatic Impairment	26	Terminated
NCT04623710	1	Renal Impairment	N/A	N/A
NCT05780645	1	Pharmacokinetics (Modified vs. Immediate Release) in Healthy Volunteers	80	Completed
NCT06071442	1	Drug-Drug Interactions in Healthy Volunteers	60	Completed

11.0 References

[1]

Works cited

1. Vemircopan | C29H28BrN7O3 | CID 126642840 - PubChem, accessed September 30, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Vemircopan
2. Vemircopan - PharmaKB, accessed September 30, 2025, https://www.pharmakb.com/drug-report/vemircopan
3. CAS 2086178-00-7 Vemircopan - BOC Sciences, accessed September 30, 2025, https://www.bocsci.com/product/vemircopan-cas-2086178-00-7-380457.html
4. Vemircopan | CAS NO.:2086178-00-7 - GlpBio, accessed September 30, 2025, https://www.glpbio.com/vemircopan.html
5. VEMIRCOPAN - precisionFDA, accessed September 30, 2025, https://precision.fda.gov/ginas/app/ui/substances/ad9195a4-3f3d-4c9c-a833-7df68f405ebc
6. Vemircopan - Alexion AstraZeneca Rare Disease - AdisInsight - Springer, accessed September 30, 2025, https://adisinsight.springer.com/drugs/800050957
7. 2086178-00-7 | Vemircopan - ChemScene, accessed September 30, 2025, https://www.chemscene.com/product/2086178-00-7.html
8. What is the mechanism of Iptacopan? - Patsnap Synapse, accessed September 30, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-iptacopan
9. Full article: The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments - Taylor & Francis Online, accessed September 30, 2025, https://www.tandfonline.com/doi/full/10.1080/17512433.2022.2109462
10. Acute post-streptococcal glomerulonephritis in children—treatment standard | Nephrology Dialysis Transplantation | Oxford Academic, accessed September 30, 2025, https://academic.oup.com/ndt/article/40/10/1843/8197890?rss=1
11. Definition of vemircopan - NCI Drug Dictionary, accessed September 30, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/vemircopan
12. www.cancer.gov, accessed September 30, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/vemircopan#:~:text=Upon%20administration%2C%20vemircopan%20targets%2C%20binds,pathway%20of%20the%20complement%20cascade.
13. Vemircopan - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 30, 2025, https://synapse.patsnap.com/drug/3f72f9469d5747fcac35e801ae446d4c
14. Exploring Treatment With Anticomplement Therapeutics | AJMC, accessed September 30, 2025, https://www.ajmc.com/view/exploring-treatment-with-anticomplement-therapeutics
15. Understanding pharmacological complement inhibition in paroxysmal nocturnal hemoglobinuria - PMC, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10905069/
16. Vemircopan (ALXN2050) Monotherapy in Paroxysmal Nocturnal Hemoglobinuria: Interim Data from a Phase 2 Open-Label Proof-of-Concept Study, accessed September 30, 2025, https://ashpublications.org/blood/article/140/Supplement%201/717/487310/Vemircopan-ALXN2050-Monotherapy-in-Paroxysmal
17. Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan - PMC - PubMed Central, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12394272/
18. Phase II Trial of Vemircopan (ALXN2050) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria - Practicing Clinicians Exchange, accessed September 30, 2025, https://practicingclinicians.com/activity/ecase/downloadsectionfile/1D7785B2-5376-43CB-8132-73A152E1085A
19. vemircopan (ALXN2050) / AstraZeneca - LARVOL DELTA, accessed September 30, 2025, https://delta.larvol.com/Products/?ProductId=4b1b0cd6-dc1d-46d9-910c-b7525b9ee646
20. Vemircopan (ALXN2050) | Complement Factor D Inhibitor | MedChemExpress, accessed September 30, 2025, https://www.medchemexpress.com/vemircopan.html
21. Vemircopan Terminated Phase 2 Trials for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment | DrugBank Online, accessed September 30, 2025, https://go.drugbank.com/drugs/DB18012/clinical_trials?conditions=DBCOND0028737&phase=2&purpose=treatment&status=terminated
22. NCT04170023 | Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy | ClinicalTrials.gov, accessed September 30, 2025, https://www.clinicaltrials.gov/study/NCT04170023
23. Vemircopan in Untreated PNH - Slideset Download - CCO, accessed September 30, 2025, https://clinicaloptions.com/activities/vemircopan-in-untreated-pnh/1000012680
24. Emerging drugs for the treatment of PNH - Biopharma PEG, accessed September 30, 2025, https://www.biochempeg.com/article/357.html
25. New Advances in the Treatment of PNH - Practical Hematologist, accessed September 30, 2025, https://www.practicalhematologist.com/paroxysmal-nocturnal-hemoglobinuria/new-advances-in-the-treatment-of-pnh/31-new-advances-in-the-treatment-of-pnh
26. Long-term ALPHA Phase III trial data showed danicopan as add-on to Ultomiris or Soliris sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular haemolysis - AstraZeneca, accessed September 30, 2025, https://www.astrazeneca.com/media-centre/press-releases/2023/long-term-alpha-phase-iii-trial-data-danicopan-ultomiris-soliris-improvement-patients-pnh-experiencing-clinically-significant-extravascular-haemolysis.html
27. NCT05218096 | Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis | ClinicalTrials.gov, accessed September 30, 2025, https://clinicaltrials.gov/study/NCT05218096
28. NCT05097989 | Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | ClinicalTrials.gov, accessed September 30, 2025, https://clinicaltrials.gov/study/NCT05097989
29. CLNP023X2203 - novctrd.com, accessed September 30, 2025, https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1215
30. Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis - PubMed Central, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12151485/
31. IgA nephropathy: a review of existing and emerging therapies - PMC - PubMed Central, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10479631/
32. AstraZeneca CEO defends 'fantastic' Alexion buyout in face of $753M hit from dropped drug - Fierce Biotech, accessed September 30, 2025, https://www.fiercebiotech.com/biotech/astrazeneca-resets-big-bets-taking-1b-charges-ex-alexion-fusion-assets-suffer-setbacks
33. AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations - BioSpace, accessed September 30, 2025, https://www.biospace.com/business/astrazeneca-axes-two-alexion-assets-as-q4-earnings-exceed-expectations
34. AstraZeneca Discontinues Wilson Disease Program, Takes $244 Million Write-Down, accessed September 30, 2025, https://globalgenes.org/raredaily/astrazeneca-discontinues-wilson-disease-program-takes-244-million-write-down/
35. AstraZeneca dumps $855M, near-approval rare disease drug after talks with regulators, accessed September 30, 2025, https://www.fiercebiotech.com/biotech/astrazeneca-dumps-855m-near-approval-rare-disease-drug-after-talks-regulators
36. ASH: As Novartis enters PNH market, AstraZeneca shows longer term effect of its latest contender - Fierce Biotech, accessed September 30, 2025, https://www.fiercebiotech.com/biotech/ash-novartis-enters-pnh-market-astrazeneca-shows-longer-term-effect-its-latest-contender
37. AstraZeneca receives US clearance of proposed acquisition of Alexion, accessed September 30, 2025, https://www.astrazeneca.com/media-centre/press-releases/2021/us-clearance-of-proposed-acquisition-of-alexion.html